Platelet and Coagulation Abnormalities in Pediatric Hematological Malignancies: Potential for Hemorrhagic Events.

IF 0.6 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2025-08-01 DOI:10.7754/Clin.Lab.2025.241241

Mohammed Makkawi, Faisal Alhajori, Sultan Alasmari

{"title":"Platelet and Coagulation Abnormalities in Pediatric Hematological Malignancies: Potential for Hemorrhagic Events.","authors":"Mohammed Makkawi, Faisal Alhajori, Sultan Alasmari","doi":"10.7754/Clin.Lab.2025.241241","DOIUrl":null,"url":null,"abstract":"Background: The purpose of the study was to evaluate the platelet counts and coagulation profiles in pediatric patients with the most common types of hematological malignancies (HMs) to assess the predisposition to thrombotic and hemorrhagic complications.Methods: This is a retrospective study carried out from 2016 to 2022. The research encompassed 172 children under the age of 16 diagnosed with HMs. The data were obtained from King Salman Medical City's Maternity and Children's Hospital in Madinah, Saudi Arabia.Results: Platelet count was statistically observed to be low in all prevalent types of HMs in our study, including B-cell acute lymphoblastic leukemia (B-ALL), acute myelomonocytic leukemia (AML-M4), T-cell acute lymphoblastic leukemia (T-ALL), and acute promyelocytic leukemia (AML-M3). The coagulation profile exhibited variability, with prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) significantly prolonged in AML-M3 patients, while only PT and INR were prolonged in other types.Conclusions: The study data reveals significant alterations in platelet count and coagulation profiles in pediatric patients with HMs, indicating an increased risk of hemorrhagic complications. The subtype of HMs may specifically influence clinical complications associated with thrombotic and hemorrhagic events and should be consid-ered in the evaluation of platelets and coagulation profiles.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 8","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2025.241241","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The purpose of the study was to evaluate the platelet counts and coagulation profiles in pediatric patients with the most common types of hematological malignancies (HMs) to assess the predisposition to thrombotic and hemorrhagic complications.

Methods: This is a retrospective study carried out from 2016 to 2022. The research encompassed 172 children under the age of 16 diagnosed with HMs. The data were obtained from King Salman Medical City's Maternity and Children's Hospital in Madinah, Saudi Arabia.

Results: Platelet count was statistically observed to be low in all prevalent types of HMs in our study, including B-cell acute lymphoblastic leukemia (B-ALL), acute myelomonocytic leukemia (AML-M4), T-cell acute lymphoblastic leukemia (T-ALL), and acute promyelocytic leukemia (AML-M3). The coagulation profile exhibited variability, with prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) significantly prolonged in AML-M3 patients, while only PT and INR were prolonged in other types.

Conclusions: The study data reveals significant alterations in platelet count and coagulation profiles in pediatric patients with HMs, indicating an increased risk of hemorrhagic complications. The subtype of HMs may specifically influence clinical complications associated with thrombotic and hemorrhagic events and should be consid-ered in the evaluation of platelets and coagulation profiles.

查看原文本刊更多论文

血小板和凝血异常在儿童血液恶性肿瘤：潜在的出血事件。

背景：本研究的目的是评估最常见的血液学恶性肿瘤（HMs）儿童患者的血小板计数和凝血情况，以评估血栓和出血性并发症的易感。方法：回顾性研究时间为2016 - 2022年。这项研究包括172名16岁以下被诊断患有HMs的儿童。数据来自沙特阿拉伯麦地那的萨勒曼国王医疗城妇幼医院。结果：我们研究中所有常见类型的HMs，包括b细胞急性淋巴母细胞白血病（B-ALL）、急性髓细胞白血病（AML-M4）、t细胞急性淋巴母细胞白血病（T-ALL）和急性早幼粒细胞白血病（AML-M3），血小板计数均有统计学意义低。凝血谱表现出变异性，AML-M3患者凝血酶原时间（PT）、活化部分凝血活素时间（APTT）和国际标准化比值（INR）显著延长，而其他类型患者仅PT和INR延长。结论：研究数据显示，儿童HMs患者血小板计数和凝血状况发生显著变化，表明出血性并发症的风险增加。HMs亚型可能特别影响与血栓和出血事件相关的临床并发症，在评估血小板和凝血情况时应予以考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.